Date:1/4/2012

, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.

'/>"/>

SOURCE Actavis Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion
2. Actavis to Launch Novel Pain Medication in the US
3. QRxPharma Announces Strategic Partnership with Actavis
4. Actavis Launches Generic KADIAN® Capsules in the U.S.
5. Actavis Plans Latin America Expansion
6. Actavis Launches Generic Keppra XR® Tablets in the U.S.
7. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
8. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
9. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
10. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
11. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.